Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.

ABSTRACT:

Importance

Nonalcoholic steatohepatitis (NASH) is projected to be the leading cause of liver transplantation by 2020. Advanced fibrosis (stage F3-F4) on liver biopsy independently predicts all-cause and liver-related mortality in NASH. There are no known efficacious treatments for advanced fibrosis related to NASH. Thiazolidinedione therapy has been extensively evaluated in NASH, and new randomized clinical trials (RCTs) of its efficacy have been completed.

Objective

To synthesize the evidence about the association of thiazolidinedione therapy with advanced liver fibrosis in NASH.

Data sources

MEDLINE, Ovid MEDLINE In-Process, Cochrane Library, EMBASE, clinicaltrials.gov, PubMed, and Scopus databases (without language restrictions), as well as other registries and sci

SUBMITTER: Musso G 

PROVIDER: S-EPMC5470366 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature